David Altshuler, EVP, Global Research and CSO at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 8,389 shares at $420.24 ($3.5M) on 2024-02-12, disclosed to the SEC on 2024-02-13.
Scheduled sale ($3.5M) by EVP, Global Research and CSO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $422.74 | 2,099 | $887K | 25.1% |
| 2 | $420.24 | 3,145 | $1.3M | 37.4% |
| 3 | $420.24 | 3,145 | $1.3M | 37.4% |
| Total | $420.87 avg | 8,389 | $3.5M | 100% |
| Filing → |
| VRTX | SELL | 2025-03-12 | $1.6M | — | Filing → |
| VRTX | SELL | 2025-03-05 | $1.6M | — | Filing → |
| VRTX | SELL | 2025-02-28 | $611K | — | Filing → |